These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 26233684)

  • 21. A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes.
    Shankar RR; Zeitler P; Deeb A; Jalaludin MY; Garcia R; Newfield RS; Samoilova Y; Rosario CA; Shehadeh N; Saha CK; Zhang Y; Zilli M; Scherer LW; Lam RLH; Golm GT; Engel SS; Kaufman KD
    Pediatr Diabetes; 2022 Mar; 23(2):173-182. PubMed ID: 34779087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
    Williams-Herman D; Johnson J; Teng R; Luo E; Davies MJ; Kaufman KD; Goldstein BJ; Amatruda JM
    Curr Med Res Opin; 2009 Mar; 25(3):569-83. PubMed ID: 19232032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
    Xu W; Mu Y; Zhao J; Zhu D; Ji Q; Zhou Z; Yao B; Mao A; Engel SS; Zhao B; Bi Y; Zeng L; Ran X; Lu J; Ji L; Yang W; Jia W; Weng J
    Sci China Life Sci; 2017 Mar; 60(3):225-238. PubMed ID: 28271251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
    Garcia de Lucas MD; Pérez Belmonte LM; Suárez Tembra M; Olalla Sierra J; Gómez Huelgas R
    Diabetes Metab; 2018 Sep; 44(4):373-375. PubMed ID: 29859992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes.
    Ji M; Xia L; Cao J; Zou D
    Medicine (Baltimore); 2016 Mar; 95(11):e2961. PubMed ID: 26986104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
    Fonseca V; Staels B; Morgan JD; Shentu Y; Golm GT; Johnson-Levonas AO; Kaufman KD; Goldstein BJ; Steinberg H
    J Diabetes Complications; 2013; 27(2):177-83. PubMed ID: 23116881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
    Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
    Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
    Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
    J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
    Kim Y; Kang ES; Jang HC; Kim DJ; Oh T; Kim ES; Kim NH; Choi KM; Kim SR; You J; Kim SJ; Lee MK
    Diabetes Obes Metab; 2019 Mar; 21(3):631-639. PubMed ID: 30362280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
    Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
    Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.
    Williams-Herman D; Johnson J; Teng R; Golm G; Kaufman KD; Goldstein BJ; Amatruda JM
    Diabetes Obes Metab; 2010 May; 12(5):442-51. PubMed ID: 20415693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
    Arechavaleta R; Seck T; Chen Y; Krobot KJ; O'Neill EA; Duran L; Kaufman KD; Williams-Herman D; Goldstein BJ
    Diabetes Obes Metab; 2011 Feb; 13(2):160-8. PubMed ID: 21199268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epicardial fat thickness in type 2 diabetes outpatient care.
    Iacobellis G; Goldberger JJ; Malavazos AE; Munoz Sterling CG; Canturk A
    Nutr Metab Cardiovasc Dis; 2024 Mar; 34(3):618-623. PubMed ID: 38151435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin.
    Engel SS; Seck TL; Golm GT; Meehan AG; Kaufman KD; Goldstein BJ
    Endocr Pract; 2013; 19(5):751-7. PubMed ID: 23757615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
    Vilsbøll T; Rosenstock J; Yki-Järvinen H; Cefalu WT; Chen Y; Luo E; Musser B; Andryuk PJ; Ling Y; Kaufman KD; Amatruda JM; Engel SS; Katz L
    Diabetes Obes Metab; 2010 Feb; 12(2):167-77. PubMed ID: 20092585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
    Goldstein BJ; Feinglos MN; Lunceford JK; Johnson J; Williams-Herman DE;
    Diabetes Care; 2007 Aug; 30(8):1979-87. PubMed ID: 17485570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study).
    Koshizaka M; Ishikawa K; Ishibashi R; Maezawa Y; Sakamoto K; Uchida D; Nakamura S; Yamaga M; Yokoh H; Kobayashi A; Onishi S; Kobayashi K; Ogino J; Hashimoto N; Tokuyama H; Shimada F; Ohara E; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Hattori A; Kitamoto T; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Takemoto M; Newby LK; Yokote K;
    Diabetes Obes Metab; 2019 Aug; 21(8):1990-1995. PubMed ID: 30993861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
    Yoon KH; Steinberg H; Teng R; Golm GT; Lee M; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study.
    Ajmani AK; Agrawal A; Prasad BLN; Basu I; Shembalkar J; Manikanth N; Subrahmanyam KAV; Srinivasa M; Chawla M; Srivastava MK; Jebasingh F; Achappa B; Agrawal RP; Pulichikkat RK; Meena R; Bhatia S; Gupta SK; Dange A; Srivastava A; Trailokya A; Shahavi V; Shende S
    Diabetes Res Clin Pract; 2019 Nov; 157():107860. PubMed ID: 31526825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.